Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

CARD PHARM : Cardiome to Hold Conference Call to Discuss First Quarter Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25/2011 | 11:56pm CEST

Vancouver, Canada, July 25th, 2011 ? Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it will hold a conference call to discuss Q1-2011 financial results and to provide a corporate update.

To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 6435784 . There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome?s website at www.cardiome.com .

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through August 26th, 2011. Please dial 905-694-9451 or 800-408-3053 and enter code 7372760# to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

For Further Information:  

Cardiome Investor Relations  (604) 676-6993 or Toll Free: 1-800-330-9928 Email: [email protected]

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words ?believe?, ?may?, ?plan?, ?will?, ?estimate?, ?continue?, ?anticipate?, ?intend?, ?expect? and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12CARDIOME PHARMA : Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECC..
04/07CARDIOME PHARMA : Announces Amendment to Term Loan Agreement with CRG-Managed Fu..
04/02CARDIOME PHARMA : Highlights Partner SteadyMed's Progress Towards Trevyent NDA R..
03/28CARDIOME PHARMA : Announces Recent Insider Purchases
03/22CARDIOME PHARMA CORP : Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts T..
03/22CARDIOME PHARMA : Health Canada Accepts Cardiome's Xydalba New Drug Submission a..
03/22CARDIOME PHARMA CORP : Blog Exposure - Cipher to Acquire Cardiome’s Canadian Bus..
03/13CARDIOME PHARMA : Reports Fourth Quarter and Full Year 2017 Financial Results
03/13CARDIOME PHARMA CORP : Cardiome Pharma Corp. to Host Earnings Call
03/06CARDIOME PHARMA : to Hold Fourth Quarter and Full Year 2017 Financial Results Co..
More news
News from SeekingAlpha
04/13Key events next week - healthcare 
03/20Midday Gainers / Losers (03/20/2018) 
03/20HEALTHCARE - TOP 5 GAINERS / LOSERS : 15 am (3/20/2018) 
03/20PREMARKET GAINERS AS OF 9 : 05 am (03/20/2018) 
03/20Cardiome to divest Canadian business to Cipher Pharma for C$25.5M 
Financials ( CAD)
Sales 2018 40,3 M
EBIT 2018 -26,9 M
Net income 2018 -27,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 2,62x
Capi. / Sales 2019 1,76x
Capitalization 106 M
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Technical analysis trends CARDIOME PHARMA CORP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 8,61  CAD
Spread / Average Target 191%
EPS Revisions
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-16.50%56 705
CSL LIMITED13.09%56 258
GRIFOLS-4.28%17 683